PMID- 32505735
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20240402
IS  - 1878-7533 (Electronic)
IS  - 1550-7289 (Print)
IS  - 1550-7289 (Linking)
VI  - 16
IP  - 9
DP  - 2020 Sep
TI  - Effects of gastric bypass surgery on expression of glucose transporters and 
      fibrotic biomarkers in kidney of diabetic fatty rats.
PG  - 1242-1248
LID - S1550-7289(20)30201-X [pii]
LID - 10.1016/j.soard.2020.04.017 [doi]
AB  - BACKGROUND: Diabetic nephropathy is the leading cause of chronic kidney disease. 
      Observational studies suggest Roux-en-Y gastric bypass (RYGB) reduces progression 
      of diabetic nephropathy. OBJECTIVES: To unravel the mechanisms by which RYGB is 
      beneficial and protective for diabetic nephropathy. SETTING: Academic 
      laboratories. METHODS: Forty-eight Zucker diabetic fatty rats were randomized to 
      RYGB, sham surgery (SHAM), or pair-fed (PF) groups. An oral glucose tolerance 
      test was performed at 25 days post intervention and kidneys were harvested at 30 
      days. Primary outcome measures included expression of key genes and proteins in 
      the glucose transport, oxidative stress, inflammation, and fibrosis pathways. 
      RESULTS: Thirty days post intervention, RYGB rats weighed 349 +/- 8 g, which was 
      lower than SHAM (436 +/- 14 g, P < .001), but not PF (374 +/- 18 g) rats. RYGB rats 
      had lower fasting glucose than PF animals and improved homeostatic model 
      assessment of insulin resistance compared with PF and SHAM groups. These enhanced 
      metabolic outcomes were accompanied by reduced sodium-glucose co-transporter 1 
      (Sglt1) gene expression (-23% versus PF, P = .01) in the kidney of RYGB rats. 
      Expression of Sglt2, Glut1, or Glut2 mRNA, or oxidative stress and inflammation 
      markers did not differ significantly. However, RYGB surgery induced a 19% lower 
      expression of transforming growth factor (Tgfbeta) mRNA (P = .004) compared with 
      SHAM treated animals. Notably, adenosine monophosphate-activated protein kinase 
      phosphorylation was increased (P = .04) in kidneys of the RYGB surgery animals. 
      CONCLUSIONS: Improvement of hyperglycemia after RYGB may reduce the glucose load 
      on the kidney leading to a downregulation of specific glucose transporters. RYGB 
      surgery may also attenuate kidney fibrosis through the adenosine 
      monophosphate-activated protein kinase/TGFbeta pathway.
CI  - Copyright (c) 2020 American Society for Bariatric Surgery. Published by Elsevier 
      Inc. All rights reserved.
FAU - Vangoitsenhoven, Roman
AU  - Vangoitsenhoven R
AD  - Bariatric and Metabolic Institute, Department of General Surgery, Cleveland 
      Clinic, Cleveland, Ohio; Department of Chronic Diseases, Metabolism and Ageing, 
      KU Leuven, Leuven, Belgium.
FAU - Mulya, Anny
AU  - Mulya A
AD  - Department of Inflammation and Immunity, Lerner Research Institute, Cleveland 
      Clinic, Cleveland, Ohio.
FAU - Mosinski, J David
AU  - Mosinski JD
AD  - Department of Inflammation and Immunity, Lerner Research Institute, Cleveland 
      Clinic, Cleveland, Ohio; Gannon University, Erie, Pennsylvania.
FAU - Brethauer, Stacy A
AU  - Brethauer SA
AD  - Bariatric and Metabolic Institute, Department of General Surgery, Cleveland 
      Clinic, Cleveland, Ohio; Department of Surgery, The Ohio State University Wexner 
      Medical Center, Columbus, Ohio.
FAU - Schauer, Philip R
AU  - Schauer PR
AD  - Bariatric and Metabolic Institute, Department of General Surgery, Cleveland 
      Clinic, Cleveland, Ohio; Pennington Biomedical Research Center, Baton Rouge, 
      Louisiana.
FAU - Kirwan, John P
AU  - Kirwan JP
AD  - Department of Inflammation and Immunity, Lerner Research Institute, Cleveland 
      Clinic, Cleveland, Ohio; Pennington Biomedical Research Center, Baton Rouge, 
      Louisiana.
FAU - Aminian, Ali
AU  - Aminian A
AD  - Bariatric and Metabolic Institute, Department of General Surgery, Cleveland 
      Clinic, Cleveland, Ohio. Electronic address: aminiaa@ccf.org.
LA  - eng
GR  - R01 DK089547/DK/NIDDK NIH HHS/United States
GR  - U54 GM104940/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20200424
PL  - United States
TA  - Surg Obes Relat Dis
JT  - Surgery for obesity and related diseases : official journal of the American 
      Society for Bariatric Surgery
JID - 101233161
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucose Transport Proteins, Facilitative)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Biomarkers
MH  - Blood Glucose
MH  - *Diabetes Mellitus
MH  - Fibrosis
MH  - *Gastric Bypass
MH  - Glucose
MH  - Glucose Transport Proteins, Facilitative
MH  - Kidney
MH  - Rats
MH  - Rats, Zucker
PMC - PMC8276306
MID - NIHMS1718894
OTO - NOTNLM
OT  - Bariatric surgery
OT  - Diabetes
OT  - Diabetic nephropathy
OT  - Gastric bypass
OT  - RYGB
OT  - Transforming growth factor
OT  - Weight loss
COIS- Disclosure statement The authors have no conflicts of interest or financial ties 
      to disclose.
EDAT- 2020/06/09 06:00
MHDA- 2021/04/28 06:00
PMCR- 2021/07/13
CRDT- 2020/06/08 06:00
PHST- 2019/10/09 00:00 [received]
PHST- 2020/03/31 00:00 [revised]
PHST- 2020/04/12 00:00 [accepted]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/06/08 06:00 [entrez]
PHST- 2021/07/13 00:00 [pmc-release]
AID - S1550-7289(20)30201-X [pii]
AID - 10.1016/j.soard.2020.04.017 [doi]
PST - ppublish
SO  - Surg Obes Relat Dis. 2020 Sep;16(9):1242-1248. doi: 10.1016/j.soard.2020.04.017. 
      Epub 2020 Apr 24.